Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2005
04/21/2005WO2005034974A1 Health food for preventing or improving thrombosis and medicinal composition for preventing or treating thrombosis
04/21/2005WO2005034972A2 Use of pharmaceutical compositions containing evening primrose oil for the treatment of xerostomia
04/21/2005WO2005034968A1 Solution for cessation of smoking and method to use
04/21/2005WO2005034967A1 Pharmaceutical or cosmetic compositions for treating skin
04/21/2005WO2005034965A1 Use of hyaluronic acid for treating sprain and strain
04/21/2005WO2005034964A1 Therapeutic formulations
04/21/2005WO2005034963A1 USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER
04/21/2005WO2005034962A1 Methods and means for modulating lipid metabolism
04/21/2005WO2005034961A1 Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof
04/21/2005WO2005034960A1 Treatment of diseases associated with the egr-1 enhancer element
04/21/2005WO2005034959A1 USE OF 2-METHYLENE-19-NOR-20(S)-1a,25-DIHYDROXYVITAMIN D3 TO INCREASE THE LIFE EXPECTANCY OF HUMAN BEINGS
04/21/2005WO2005034958A1 Triterpene compounds which are effective on improvement of brain function
04/21/2005WO2005034957A1 Noncrystalline antibacterial composition containing cefditoren pivoxil
04/21/2005WO2005034956A1 Antimycotic nail polish formulations comprising substituted 2-aminothiazoles as an active substance
04/21/2005WO2005034954A2 Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
04/21/2005WO2005034953A1 Angiogenesis inhibitor
04/21/2005WO2005034952A2 Isoxazole and isothiazole compounds useful in the treatment of inflammation
04/21/2005WO2005034951A1 Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
04/21/2005WO2005034950A1 Pyridothiophene compounds
04/21/2005WO2005034948A1 Solid dosage formulation containing a factor xa inhibitor and method
04/21/2005WO2005034946A1 Nonsedating α-2 agonist 1- (2, 3-dimethyl-phenyl) -ethyl-1, 3-dihydro-imizadole-2-thione
04/21/2005WO2005034945A1 Use of norphenazone and coenzyme q for curing arthrose, arthritis and osteoarthritis
04/21/2005WO2005034944A1 Combinations of indole compounds and alkylating agents for the treatment of cancer
04/21/2005WO2005034943A1 Indole antiviral compositions and methods
04/21/2005WO2005034942A1 Animal feed composition
04/21/2005WO2005034940A2 Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases
04/21/2005WO2005034939A1 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics
04/21/2005WO2005034938A1 Collagen productin enhancer and production process and use thereof
04/21/2005WO2005034937A1 Composition for treatment of osteoarthritis containing apigenin as chindroregenerative agent
04/21/2005WO2005034935A1 Use of organoarsenic or organoantimony derivatives for their anticancer properties
04/21/2005WO2005034934A1 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucleic acid replication (e.g. aciclovir)
04/21/2005WO2005034933A1 Inhibitors of yeast filamentous growth and method of their manufacture
04/21/2005WO2005034932A2 Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function
04/21/2005WO2005034931A1 Pharmaceutical compositions comprising malonamide derivatives for decreasing sebum production
04/21/2005WO2005034930A1 Pellets containing venlafaxine hydrochloride
04/21/2005WO2005034929A2 Tissue remodeling and vascularization
04/21/2005WO2005034928A1 Rapid dissolution formulation of a calcium receptor-active compound
04/21/2005WO2005034927A2 Aerosol formulation comprising formoterol in suspension
04/21/2005WO2005034924A1 Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
04/21/2005WO2005034922A1 Compositions for conjugated estrogens and associated methods
04/21/2005WO2005034921A1 Rapidly disintegrating formulation
04/21/2005WO2005034920A1 A solid dosage form comprising a fibrate
04/21/2005WO2005034919A2 Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
04/21/2005WO2005034916A1 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin
04/21/2005WO2005034913A1 Novel liquid preparation composition
04/21/2005WO2005034912A2 Ferromagnetic particles and methods
04/21/2005WO2005034911A1 Aerosol formulations comprising formoterol fumarate dihydrate, a propellant,ethanol and optionally a steroid,where the formoterol fumarate dihydrate has a water content of 4.8-4.28% by weight
04/21/2005WO2005034910A1 Oral liquid pharmaceutical compositions of sertraline
04/21/2005WO2005034908A2 A solid dosage form comprising a fibrate and a statin
04/21/2005WO2005034902A1 Composition for promoting collagen production
04/21/2005WO2005034901A1 Use of a combination of cromoglicic acid and/or one of the salts and/or esters thereof and a gelling agent, and cosmetic or pharmaceutical applications thereof
04/21/2005WO2005034900A1 Cosmetic or pharmaceutical preparations containing oligo and/or polysaccharides for the treatment of epithelial covering tissue
04/21/2005WO2005034890A2 Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
04/21/2005WO2005034883A2 A method of healing skin wounds in mammals and a composition therefor
04/21/2005WO2005034882A2 Composition and method to treat solid tumors
04/21/2005WO2005034881A2 Methods and compositions for treating conditions involving abnormal angiogenesis
04/21/2005WO2005034880A2 Thiophene and benzothiophene hydroxamic acid derivatives
04/21/2005WO2005034879A2 Treatment of diseases involving erbb2 kinase overexpression
04/21/2005WO2005034874A2 Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
04/21/2005WO2005034873A2 A method for reducing anti-neoplastic agent induced side-effects
04/21/2005WO2005034871A2 Methods for treating diseases and conditions with inverse agonists
04/21/2005WO2005034870A2 Amide compounds and ion channel ligands and uses thereof
04/21/2005WO2005034869A2 Compounds and compositions as protein kinase inhibitors
04/21/2005WO2005034868A2 Methods for treating igf1r-inhibitor induced hyperglycemia
04/21/2005WO2005034866A2 Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
04/21/2005WO2005034860A2 Thiol reactive agents as a therapeutic modality
04/21/2005WO2005034859A2 Extended release formulations of opioids and method of use thereof
04/21/2005WO2005034858A2 Compositions and methods for treatment of muscle pain and muscle wasting
04/21/2005WO2005034856A2 Targeted drug-formaldehyde conjugates and methods of making and using the same
04/21/2005WO2005034854A2 Water dispersible film
04/21/2005WO2005034849A2 Methods for identifying improved, non-sedating alpha-2 agonists
04/21/2005WO2005034848A2 Inhibitors of cathepsin s
04/21/2005WO2005034847A2 Methods of reducing risk of infection from pathogens
04/21/2005WO2005034846A2 Withanamide and withanolide compositions and method of use thereof
04/21/2005WO2005034845A2 Compositions and methods for treatment of cancer
04/21/2005WO2005034839A2 Porifera-based therapeutic compositions for treating and preventing skin diseases
04/21/2005WO2005034838A2 Protease inhibitors
04/21/2005WO2005034837A2 7H-IMIDAZO [1,2-α] PYRAZIN-8-ONE COMPOUNDS AS ION CHANNEL MODULATORS
04/21/2005WO2005034737A2 Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases
04/21/2005WO2005034728A2 Colon cleansing composition and method
04/21/2005WO2005034726A2 Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
04/21/2005WO2005034650A1 Weight-loss supplement
04/21/2005WO2005034626A1 Insect repellent compositions comprising dihydronepetalactone
04/21/2005WO2005023807A3 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
04/21/2005WO2005023310A3 Polyamine-metal chelator conjugates
04/21/2005WO2005023306A3 Combination of medicaments comprising lansoprazole and domperidone
04/21/2005WO2005020965A3 Skeletally targeted nanoparticles
04/21/2005WO2005020928A3 Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
04/21/2005WO2005020882A3 Compound capable of binding s1p receptor and pharmaceutical use thereof
04/21/2005WO2005017160A3 Mobilization of hematopoietic cells
04/21/2005WO2005017129B1 Phosphoramide and uses thereof
04/21/2005WO2005016229A3 Use of lipophilic diesters of chelating agent for the treatment of amyloidosis and atherosclerosis
04/21/2005WO2005013907A3 Pyrrolo[1,2-b]pyridazine derivatives
04/21/2005WO2005012210A3 Antimicrobial active preparations containing terpene derivatives
04/21/2005WO2005011737A3 Pharmaceutical combinations and formulations with improved stability
04/21/2005WO2005011697A3 Sulfonamide derivatives with activity on protein kinase a and b
04/21/2005WO2005010202A3 PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS
04/21/2005WO2005009421A3 The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
04/21/2005WO2005007876A3 Modulation of interleukin-10 by dhea
04/21/2005WO2005007083A3 Chemical compounds
1 ... 4713 4714 4715 4716 4717 4718 4719 4720 4721 4722 4723 4724 4725 4726 4727 4728 4729 4730 4731 4732 4733 ... 7860